Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

311
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
311
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

272
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
272
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

380
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
380
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

9.2K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.2K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

337
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
337
Drug Therapy01:28

Drug Therapy

96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
96

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum Aripiprazole Concentrations After Inadvertent Intradeltoid Administration of Aripiprazole Lauroxil 1064 mg: A Case Report.

Therapeutic drug monitoring·2026
Same author

2023 MHC Awards and Recognition.

The mental health clinician·2024
Same author

Differences in serum concentration with valproate oral solution versus delayed-release divalproex in an adherent patient.

The mental health clinician·2024
Same author

2022 MHC Awards and Recognition.

The mental health clinician·2023
Same author

2021 MHC Awards and Recognition.

The mental health clinician·2022
Same author

Toxic clozapine level as first indication of severe, acute infection.

The mental health clinician·2022
Same journal

Are the 8 Finnish Deaths Explained by Agranulocytosis More Important than the Thousands of Suicide Deaths Associated with the Lack of Use of Clozapine? Reflections on Clozaphobia.

Journal of clinical psychopharmacology·2026
Same journal

Aripiprazole Withdrawal-Associated Restless Legs Syndrome During Clozapine Treatment in an Adolescent With Schizoaffective Disorder: A Case Report.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
Same journal

Article Selected to Receive the Mitchell B. Balter Award for Publications in 2025.

Journal of clinical psychopharmacology·2026
Same journal

Pregnancy Outcomes After First-Trimester Exposure to Vortioxetine: Prospective Outcomes From the MGH National Pregnancy Registry for Psychiatric Medications.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
See all related articles

Related Experiment Video

Updated: Sep 8, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K

Probable Interaction Between Aripiprazole and Isoniazid

Erica A K Davis, Leo T Batongbakal

    Journal of Clinical Psychopharmacology
    |June 13, 2022
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
    09:34

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

    Published on: August 16, 2021

    1.9K
    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
    10:29

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

    Published on: May 9, 2025

    1.5K

    Related Experiment Videos

    Last Updated: Sep 8, 2025

    Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
    06:14

    Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

    Published on: October 15, 2017

    8.4K
    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
    09:34

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

    Published on: August 16, 2021

    1.9K
    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
    10:29

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

    Published on: May 9, 2025

    1.5K